Novel alkoxypyridine-derivatives

Details for Australian Patent Application No. 2003226706 (hide)

Owner ALTANA PHARMA AG

Inventors Marx, Degenhard; Barsig, Johannes; Eltze, Manfrid; Boer, Rainer; Ulrich, Wolf-Rudiger; Fuchss, Thomas; Klein, Thomas; Gradler, Ulrich; Nave, Rudiger

Agent Griffith Hack

Pub. Number AU-A-2003226706

PCT Number PCT/EP03/03076

PCT Pub. Number WO2003/080607

Priority 02007049.6 27.03.02 EP

Filing date 25 March 2003

Wipo publication date 8 October 2003

International Classifications

C07D 471/04 Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups

C07D 473/00 Heterocyclic compounds containing purine ring systems

A61K 031/4427 - containing further heterocyclic ring systems

A61K 031/52

A61P 025/00 Drugs for disorders of the nervous system

Event Publications

7 August 2003 Complete Application Filed

  Priority application(s): 02007049.6 27.03.02 EP

13 November 2003 Application Open to Public Inspection

  Published as AU-A-2003226706

22 October 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2003226707-CONTINUOUS CASTING MOULD FOR LIQUID METALS, ESPECIALLY FOR LIQUID STEEL

2003226705-4-(N-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitors